Enlivex Therapeutics Ltd
NASDAQ:ENLV

Watchlist Manager
Enlivex Therapeutics Ltd Logo
Enlivex Therapeutics Ltd
NASDAQ:ENLV
Watchlist
Price: 1.23 USD -0.81% Market Closed
Market Cap: 27m USD
Have any thoughts about
Enlivex Therapeutics Ltd?
Write Note

Net Margin
Enlivex Therapeutics Ltd

0%
Current
0%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-22.3m
/
Revenue
0

Net Margin Across Competitors

Country Company Market Cap Net
Margin
IL
Enlivex Therapeutics Ltd
NASDAQ:ENLV
25.7m USD N/A
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
318.1B USD
9%
US
Amgen Inc
NASDAQ:AMGN
142.2B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
117.1B USD
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.2B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
135.7B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36.2B EUR
-14%
Country IL
Market Cap 25.7m USD
Net Margin N/A
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 318.1B USD
Net Margin
9%
Country US
Market Cap 142.2B USD
Net Margin
13%
Country US
Market Cap 117.1B USD
Net Margin
0%
Country US
Market Cap 105.2B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 135.7B AUD
Net Margin
18%
Country US
Market Cap 78.7B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36.2B EUR
Net Margin
-14%
No Stocks Found

Enlivex Therapeutics Ltd
Glance View

Market Cap
25.7m USD
Industry
Biotechnology

Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

ENLV Intrinsic Value
1.18 USD
Overvaluation 4%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-22.3m
/
Revenue
0
What is the Net Margin of Enlivex Therapeutics Ltd?

Based on Enlivex Therapeutics Ltd's most recent financial statements, the company has Net Margin of 0%.